Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/73741
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | A bivalent Neisserie meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial |
Author: | Richmond, P. Nissen, M. Marshall, H. Lambert, S. Roberton, D. Gruber, W. Jones, T. Arora, A. |
Citation: | Vaccine, 2012; 30(43):6163-6174 |
Publisher: | Elsevier Sci Ltd |
Issue Date: | 2012 |
ISSN: | 0264-410X 0264-410X |
Statement of Responsibility: | P.C. Richmond, M.D. Nissen, H.S. Marshall, S.B. Lambert, D. Roberton, W.C. Gruber, T.R. Jones and A. Arora |
Abstract: | Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed and available. The conserved, outer-membrane lipoprotein factor H binding protein (fHBP, also known as LP2086) is expressed as one of two subfamily variants in virtually all meningococci. This study investigated the safety, tolerability, and immunogenicity of a recombinant-expressed bivalent fHBP (r-fHBP) vaccine in healthy adults. Participants (N=103) aged 18-25 years were recruited into three ascending dose level cohorts of 20, 60, and 200μg of a bivalent r-fHBP vaccine formulation and randomised to receive vaccine or placebo at 0, 1, and 6 months. The vaccine was well tolerated. Geometric mean titres (GMTs) for r-fHBP subfamily-specific IgG antibodies increased 19-168-fold from pre-vaccination to post-dose 2 in a dose level-dependent manner. In addition, robust serum bactericidal assay using human complement (hSBA) responses for strains expressing both homologous and heterologous fHBP variants were observed. After three vaccinations, 16-52% of the placebo group and 47-90%, 75-100%, and 88-100%, of the 20, 60, and 200μg dose levels, respectively, had seroprotective (≥ 1:4) hSBA titres against six serogroup B strains. The bivalent r-fHBP vaccine was well tolerated and induced robust bactericidal activity against six diverse serogroup B strains in young adults at the 60 and 200μg dose levels. |
Keywords: | Humans Neisseria meningitidis, Serogroup B Meningococcal Infections Bacterial Proteins Immunoglobulin G Vaccines, Synthetic Meningococcal Vaccines Antibodies, Bacterial Antigens, Bacterial Double-Blind Method Adult Complement System Proteins Female Male Young Adult Serum Bactericidal Antibody Assay |
Rights: | © 2012 Elsevier Ltd. |
DOI: | 10.1016/j.vaccine.2012.07.065 |
Published version: | http://dx.doi.org/10.1016/j.vaccine.2012.07.065 |
Appears in Collections: | Aurora harvest 4 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.